Compare MDV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | TLSA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United Kingdom |
| Employees | 12 | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.4M | 155.2M |
| IPO Year | N/A | 2017 |
| Metric | MDV | TLSA |
|---|---|---|
| Price | $14.70 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.7K | ★ 104.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.62 | $0.73 |
| 52 Week High | $17.15 | $2.60 |
| Indicator | MDV | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 46.13 |
| Support Level | $14.11 | $1.29 |
| Resistance Level | $14.96 | $1.61 |
| Average True Range (ATR) | 0.40 | 0.10 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 13.72 | 37.84 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.